Study of IL-12 Treatment in Ovarian Cancer Patients
Author Information
Author(s): Lenzi Renato, Edwards Robert, June Carl, Seiden Michael V, Garcia Michael E, Rosenblum Michael, Freedman Ralph S
Primary Institution: The University of Texas M.D. Anderson Cancer Center
Hypothesis
Can intraperitoneal recombinant interleukin-12 (rhIL-12) improve outcomes in patients with peritoneal carcinomatosis associated with ovarian cancer?
Conclusion
IP IL-12 can safely be administered at this dose and schedule to patients after first line chemotherapy for ovarian/peritoneal carcinoma, but the maximum response observed was stable disease.
Supporting Evidence
- Thirty-four patients were registered for the first screening phase of the study.
- Twelve patients completed the second phase and were evaluable for response/toxicity.
- The best response observed was stable disease in 2 patients.
Takeaway
Doctors tested a new treatment for ovarian cancer using a special medicine called IL-12, but it didn't help most patients get better.
Methodology
A phase 2 multi-institutional trial was conducted with patients receiving IP rhIL-12 weekly after surgery.
Limitations
Only 12 of 34 patients were eligible for treatment, and the study was closed early due to lack of responses.
Participant Demographics
Median age was 56.6 years; 31 white, 2 black, and 1 Asian.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website